Drugs / LM-350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07112222 | Aug 2025 → Jun 2028 expected | cancer | LaNova Medicines Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗
2025年，中国生物制药共有3款ADC药物（包括1款双抗ADC）首次获批临床，构建了覆盖不同靶点的ADC创新矩阵。 |
| 2025-11-17 | LaNova Medicines Limited | Regulatory LM-350获得中国NMPA的IND批件 lanovamedicines.com ↗
礼新医药宣布其自主研发的创新药LM-350（CDH17 抗体偶联药物）已获得中国国家药物监督管理局(NMPA)的新药临床试验（IND）批件。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 中国生物制药2025年18款1类新药首次获批临床，全球化研发体系再深化 cttq.com ↗ |
| 2025-11-17 | LaNova Medicines Limited | LM-350获得中国NMPA的IND批件 lanovamedicines.com ↗ |
| 2025-07-24 | LaNova Medicines Limited | LM-350「CDH17 ADC」获得美国FDA的IND批件 lanovamedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM-350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07112222 ↗ |
| Route | Intravenous | “Intravenous Drip” NCT07112222 ↗ |